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provide a more precise prognostication of survival for patients 
with OCSCC compared to TNM staging. Further investigation of 
these prognostic roles is merited to allow individual patient risk-
stratification and may help in treatment decision and trial 
design. 
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Purpose: To compare outcomes among patients with localized 
esophageal and gastro-esophageal junction (GEJ) cancer who 
received concomitant chemo-radiation (CRT) using either 
cisplatin/5-FU or carboplatin/paclitaxel. CROSS 
trial demonstrated efficacy of carboplatin/paclitaxel in tri-
modality setting. However this regimen has also been 
adopted as an alternate for patients receiving CRT as 
definitive treatment due to better tolerance. 
Methods and Materials: Medical records of all patients diagnosed 
with localized carcinoma of esophagus and GEJ who underwent 
definitive CRT using cisplatin/5-FU, carboplatin/5-FU, or 
carboplatin/paclitaxel between January 2008 and March 2015 at 
our academic centre were reviewed. 
Results: Seventy-five patients (79% male) were identified with a 
median age of 74 years (range 45-86). Most (66%) had an 
adenocarcinoma and 37% squamous cell carcinoma. Sixty-three 
percent had distal 1/3rd and/or GEJ tumour. 48% received 
cisplatin/5-FU, 35% carboplatin/paclitaxel and 17% 
carboplatin/5-FU. Most patients (99%) received 50Gy in 25 
fractions. The median overall survival (OS) for cisplatin/5-FU 
group was 27 months (m) (95%CI 17-39) with three-year OS of 
42%, in contrast to 14 m (95%CI 11-17) and 13% among patients 
received carboplatin/paclitaxel (log-rank p = 0.006). The median 
OS for carboplatin/5-FU group was 17 m (95%CI 11-81) with 
three-year OS of 38%. Cisplatin/ 5-FU group had a significantly 
better distant metastasis free survival (median 20 versus 11 m, 
p = 0.04) when compared to carboplatin/paclitaxel group. On 
multivariate analysis, cisplatin/5-FU (hazard ratio(HR) 0.45, p = 
0.023) and carboplatin/5-FU group (HR 0.46, p = 0.093) were 
found to be associated with OS adjusted for other patient, 
disease and treatment related characteristics. 
Conclusions: We report that patients receiving cisplatin/5-FU 
had a significant survival benefit compared to patients who 
received carboplatin/paclitaxel as a definitive treatment for 
esophageal and GEJ cancer. Carboplatin/ 5FU might be a 
reasonable alternate for highly select patients. Clinical trials 
regarding optimal chemotherapy regimen are warranted for 
patients who are not surgical candidates. 
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Purpose: All studies to date have evaluated the dosimetric effect 
of bladder deformation using an organ model that includes the 
dose to the urine. This research reconstructed bladder dose using 
both hollow and solid organ models, to determine if dose/volume 
differences exist. 
Methods and Materials: Thirty-five prostate IMRT patients were 
selected, who had received 78 Gy in 39 fractions and full bladder 
instructions. Biomechanical modeling and finite element analysis 
was used to reconstruct bladder dose (solid and hollow organ 
model) using every third CBCT throughout the treatment course. 
Results: Reconstructed bladder dose was 11.3 Gy greater than 
the planned dose with a hollow model (p < 0.001) and 12.3Gy 
greater with a solid model (p < 0.0001). Median reconstructed 
volumes within the 30 Gy, 65 Gy and 78 Gy isodoses were 3-4 
times larger with the solid bladder model (p < 0.0001). Using a 
solid bladder model resulted in a difference between planned 
and reconstructed dose that was 10% larger than when using a 
hollow model. The difference between planning bladder volume 
and median treatment volume was associated with the 
difference between the planned and reconstructed dose below 
78 Gy (R2 > 0.61). 
Conclusions: Substantial differences exist between planned and 
reconstructed bladder dose, associated with the differences in 
bladder filling between planning and treatment. Dose 
reconstructed using a solid bladder model over-reports the 
volume of bladder within key isodose levels and overestimates 
the differences between planned and reconstructed dose. Dose 
reconstruction with a hollow organ model is recommended if the 
goal is to associate that dose with toxicity. 
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LATE TOXICITY AFTER TBI IN AHCT FOR RELAPSED FOLLICULAR 
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Purpose: Follicular lymphoma (FL) is a progressive relapsing 
hematologic malignancy. At The Ottawa Hospital (TOH), 
autologous hematopoietic cell transplantation (AHCT) utilizing 
total body irradiation (TBI) has been used to treat relapsed FL 
patients for over 20 years. We reviewed our large single 
institution experience and assessed outcomes and late toxicity. 
Methods and Materials: We retrospectively reviewed 
consecutive patients undergoing AHCT for relapsed FL from July 
1991 to February 2013. The pre-AHCT conditioning regimen was 
commonly Etoposide/Melphalan/TBI. Patients received TBI on a 
linear accelerator using a translating-bed technique. The total 
dose was 5 Gy/1fr for 92% of patients, the remainder received 
12Gy/6fr. Lung attenuators were used to maintain dose 
homogeneity. Patient information was stored on our bone 
marrow transplant (BMT) database. Descriptive statistics were 
calculated for all relevant demographic variables. Overall 
survival was estimated from the BMT date using the Kaplan-Meier 
method. Second malignancies were reported. Late toxicity was 
assessed in patients with at least one year of follow up (FU). 
Lung, kidney and thyroid toxicity was evaluated through 
extensive chart reviews. Clinical toxicity, creatinine, PFTs, chest 
imaging, thyroid function tests were assessed pre-AHCT and 
post-AHCT. 
Results: We evaluated 174 patients with a median age of 50 years 
at transplant. There were 106 men and 68 women. Median follow 
up was 6.0 years. Median follow up among survivors was 8.3 
years. Overall survival at one, five, 10 and 15 years was 93%, 
73%, 57% and 47% respectively. Eighteen patients (10.3 %) 
developed a second malignancy; 11 (6.3%) had solid tumours, two 
(1.1%) had AML and five (2.9%) developed myelodysplastic 
syndrome. Median time to second malignancy was 7.2 years, with 
cumulative incidences of developing second cancer at 5% and 8% 
at five and 10 years. We evaluated 149 patients with at least one 
year of follow up. Of 80 assessable patients, 23% developed 
hypothyroidism; 3% were hypothyroid beforehand. Pre-AHCT, 
creatinine ranged from 41 to 139 umol/L. Post AHCT, at last FU, 
of 116 patients, creatinine (umol/L) was < 100 in 63%, 100-150 
in 20%, 151-200 in 6% and > 200 in 9%. Hemodialysis was required 
for two patients. Clinical lung toxicity was noted in 6% of 95 
patients. PFTs were recorded in 26 patients pre-AHCT and 46 
patients post-AHCT. Abnormalities in DLCO were noted in 17% 
pre-AHCT and 26% of post-AHCT. Abnormalities in FEV1 were 
noted in 11% pre-AHCT and 25% of post-AHCT. Radiologic 
abnormalities were noted in 39%, with 23% being fibrotic 
changes, possibly radiation-induced, and 17% likely unrelated. 
Conclusions: Our results with TBI-based AHCT for relapsed FL are 
very good, with most patients surviving 10 years post-AHCT. 
